MariTide (Maridebart Cafraglutide): The Monthly GLP-1 Antibody-Conjugate (2026 Update)

MariTide is Amgen's entry into the late-stage obesity-pharmacology pipeline. The compound, known generically as maridebart cafraglutide and formerly designated AMG-133, is a peptide-antibody conjugate with a fundamentally different administration profile than the prevailing GLP-1 class: once per month, by subcutaneous injection, rather than once per week.

This post covers what MariTide is, how its mechanism is different from tirzepatide and other dual-receptor agents, what trials have shown, where it sits in the regulatory pipeline as of May 2026, and what monthly dosing actually changes for the prescribing landscape. MariTide is not approved. No responsible prescriber writes it for obesity in 2026. It is on the short list of late-stage compounds with the potential to materially shift the access conversation if approved.

What MariTide is

MariTide is a peptide-antibody conjugate. That description has three components, each meaningful:

1. Peptide component. A peptide that activates the GLP-1 receptor — the same target as semaglutide, liraglutide, the GLP-1 portion of tirzepatide.
2. Antibody component. A monoclonal antibody fragment that targets the GIP receptor as an antagonist — the opposite direction from tirzepatide, which agonizes GIP.
3. Conjugate architecture. The peptide is covalently linked to the antibody. The result is a single molecule with two pharmacologic actions. The antibody half of the molecule provides the long half-life that supports monthly dosing; antibodies have intrinsically long circulation half-lives by virtue of their size and FcRn-mediated recycling.

This is mechanistically different from anything in the approved GLP-1 landscape. Tirzepatide is a small peptide with both GLP-1 and GIP agonism in a single sequence. Retatrutide is a peptide with three agonisms. MariTide is a hybrid molecule — peptide + antibody — with one agonism (GLP-1) and one antagonism (GIP), with the antibody scaffold dictating the duration of action.

Why GIP antagonism rather than agonism

This is the most-debated mechanistic question about MariTide. Tirzepatide showed that GIP agonism, combined with GLP-1, produces stronger weight loss and arguably better tolerability than GLP-1 alone. So why would a competitor go in the opposite direction?

The case for GIP antagonism rests on a long-standing genetic and physiologic literature suggesting that GIP signaling has metabolic effects in the obese state that are different from its effects in the lean state. Specifically: blocking GIP signaling in models of obesity has been associated with weight loss, while activating it has the same effect through different cellular pathways. Both directions can produce similar phenotypic outcomes — weight loss — through different mechanisms. Phase 2 data on MariTide supported the bidirectional pharmacology hypothesis: a GLP-1 agonist + GIP antagonist combination produced clinically meaningful weight loss at competitive magnitudes.¹

The practical implication for prescribers and patients is that MariTide and tirzepatide will likely both be available in the post-approval landscape, with patients sorting between them based on tolerability profile, dosing frequency preference, and individual response. They are not direct mechanism analogs; they are different combinations producing comparable outcomes.

What the trials have shown

MariTide has progressed through phase 1 and phase 2 with phase 3 in flight as of 2026.

Phase 2 obesity. Reported mean body-weight reductions in the high teens to low 20% range at the trial's longest follow-up at the higher doses tested. Placebo-corrected efficacy was robust. The dose-response was visible. Tolerability was qualitatively similar to other GLP-1-class agents — gastrointestinal events concentrated in the dose-escalation phase, with monthly dosing creating a different titration cadence than weekly agents.

Durability. One of the questions in phase 2 was whether monthly dosing produces stable, durable effects across the dosing interval. The data so far supports flat or near-flat plasma concentration profiles across the month — consistent with the long half-life of antibody-conjugate molecules — and no obvious dose-end "wear off" effects in symptom or weight metrics.

Phase 3. Multiple phase 3 trials are in flight in obesity and adjacent indications. Readouts have begun to appear through 2026 with the largest readouts expected through 2027.

The headline takeaway is that MariTide is competitive with the highest-tier injectable agents on raw weight loss, with monthly rather than weekly dosing. That combination, if it holds in phase 3, is meaningfully different from what is currently approved.

Where the regulatory state stands as of May 2026

• Approval status: Not approved.
• Phase: Phase 3.
• FDA submission: Expected in the 2027 window depending on phase 3 readout timing.
• Earliest plausible decision: 2027 to 2028.
• Compounded versions: None. The peptide-antibody conjugate architecture is not within the scope of 503A compounding. Any "compounded MariTide" claim is misrepresenting what is being sold.

This is the honest regulatory read. There is no early access route to MariTide. The compounds that have circulated as "MariTide-like" peptides are not MariTide; they are research-grade peptides with no relationship to the approved drug development program.

Why monthly dosing actually matters

The case for monthly dosing as a differentiator rests on adherence. Three observations:

Real-world adherence to weekly GLP-1 is imperfect. Pharmacy refill data and clinical-trial-versus-real-world comparisons consistently show that adherence in routine clinical practice is below trial-protocol adherence. Some fraction of patients miss doses; some delay between doses; some discontinue because the weekly cadence is friction.

Monthly dosing changes the friction equation. A monthly injection is a scheduled event that integrates into a once-a-month cadence — like a longer-acting hormonal contraceptive or a slow-release depot medication in psychiatry. Patients who experience the weekly cadence as friction often respond to monthly cadence as substantially less burdensome.

Travel and supply. Monthly dosing means one injection device per month rather than four pens. The supply, refrigeration, and travel implications are simpler. For patients who travel frequently, the simplification is meaningful.

The trade-off is that monthly dosing is less forgiving of dose-escalation errors. If a patient at a higher dose experiences side effects, the next "dose decision" is a month away rather than a week. Phase 3 protocols and label development will need to address how dose escalation and adjustment are managed in a monthly framework. That is a soluble problem; it is not a barrier.

What MariTide approval would change

If MariTide is approved on the timelines suggested by current phase 3 readouts:

1. Adherence-friendly first-line option. For patients who decline weekly injection on adherence or friction grounds, MariTide becomes a default first-line choice in the post-approval landscape.
2. Re-segmentation of the GLP-1 market. The current segmentation is roughly: oral semaglutide (low efficacy, high friction), injectable semaglutide (mid efficacy, weekly), injectable tirzepatide (high efficacy, weekly). MariTide adds a row: high efficacy, monthly. The expected outcome is that segments overlap rather than entirely substitute, but the highest-friction patients sort toward monthly.
3. Pricing pressure. A new high-efficacy, less-frequent-dosing entrant typically creates price competition. Whether that translates to lower retail prices for patients depends on launch strategy and payer dynamics.
4. Compounding-market constraint. MariTide is not compoundable. The compounding market segment that has formed around weekly peptide GLP-1s does not extend to MariTide. Patients on compounded weekly GLP-1 cannot translate that experience to MariTide; they would have to move to the branded approved product.

The competitive landscape for MariTide is not just tirzepatide and semaglutide. It includes retatrutide (if approved on a 2027 timeline), oral orforglipron (if approved on a 2027 timeline), and CagriSema (if approved on a 2026-2027 timeline). The post-2027 GLP-1 prescribing landscape will be substantially more crowded than the current state.

TelePeptide's prescribing posture

TelePeptide will offer MariTide only after FDA approval and only through pharmacy channels that handle the approved branded manufactured product. The reasons:

• Not approved is not approved. A peptide-antibody conjugate in phase 3 is not a prescribable medication. Sources claiming to offer it are selling something else.
• Architecture-specific manufacturing. Even if the peptide component could be compounded, the antibody component is a biologic that requires biologics-grade manufacturing. The conjugate as a whole is not a compoundable product.
• Standard of care. Investigational compounds in phase 3 are not within the standard of care for general clinical use. Prescribing them as if they were approved is not consistent with how this works.

When MariTide is approved, TelePeptide's prescribing posture is to offer it within label, with the same direct-pay transparent-pricing model we apply to currently approved compounds.

What to watch through 2026 and 2027

For patients tracking MariTide:

1. Phase 3 efficacy readouts. Mean weight loss, dose-response, time-course of effect, durability across the monthly dosing interval. Topline readouts have begun and will continue.
2. Phase 3 safety data. Cardiovascular signals, gastrointestinal tolerability, antibody-conjugate-specific concerns (immunogenicity, injection-site reactions).
3. FDA submission. Submission timing is the strongest signal of decision timing.
4. Approval decision and label. Indications, dosing schedule, contraindications. The label determines who is eligible to be prescribed and under what circumstances.

Until those events resolve, the right action for patients is the same as for orforglipron and retatrutide: track the watchlist, base current treatment on currently approved compounds, revisit at the next quarterly pipeline update.

Bottom line

MariTide (maridebart cafraglutide) is the most differentiated late-stage GLP-1-class compound on the basis of administration profile: monthly dosing, achieved through a peptide-antibody conjugate architecture, with phase 2 efficacy in the high-teens to low-20% weight-loss range. It is not approved. The earliest plausible FDA decision is 2027 to 2028. Compounded versions do not exist and cannot exist within 503A scope. Patients interested in monthly GLP-1 should track phase 3 readouts and continue to base 2026 prescribing decisions on what is actually approved.

Footnotes

1. Amgen MariTide phase 2 readouts, public conference presentations and journal publications, 2023-2025. ↩